Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in metastatic castration-resistant prostate cancer (mCRPC).

GTx-758 is a selective estrogen receptor alpha agonist that potentially has multiple mechanisms of action, including upregulating sex hormone binding globulin (SHBG) and lowering free testosterone levels.

In this trial, patients with mCRPC being treated with leuprorelin (Lupron) with low testosterone received low-dose (125 mg per day) GTx-758. These patients saw upregulated SHBG and decreased free testosterone levels, which translated into PSA declines. Researchers plan to analyze GTx-758 at 250 mg per day.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Fred Hutch Cancer Center

Cancer Centers

Partner

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Dr. Yu Discusses the Utility of GTx-758 in mCRPC